News & Updates

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

20 Nov 2023 by

Use of antihypertensive medications does not appear to reduce the risk of all-cause mortality in patients with heart failure (HF) with preserved ejection fraction (HFpEF), reports a study presented at AHA 2023. However, treatment with antihypertensives can lower the risk of adverse cardiovascular (CV) outcomes regardless of the patient’s hypertension status.

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

20 Nov 2023

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023 by

Treatment with dapagliflozin results in a lower risk of worsening heart failure (HF) or cardiovascular death and improvements in symptoms among patients with HF and type 2 diabetes (T2D), with or without neuropathy, according to a study presented at AHA 2023. However, the beneficial effects of dapagliflozin appears more evident in those with neuropathy.

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023

Secondary hypertension prevalent in hypertensive children, especially girls

19 Nov 2023

A recent study in China has found that secondary hypertension is still the most common type of hypertension among children, particularly in girls, during the past decade. The dominant cause of this condition is renal diseases, followed by rheumatic immune diseases.

Secondary hypertension prevalent in hypertensive children, especially girls

19 Nov 2023

Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity

19 Nov 2023

People with high or medium genetic risk of abdominal obesity but who have a healthy lifestyle are less likely to develop coronary heart disease (CHD) than those with low genetic risk and an unhealthy lifestyle, a study has shown.

Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity

19 Nov 2023

6-month resistance training eases platelet activation in hypertensive women

18 Nov 2023

Resistance training is effective in reducing platelet aggregation by modulating the purinergic system in hypertensive women, suggests a recent study, which shows an association between purinergic signaling and platelet activation in hypertension.

6-month resistance training eases platelet activation in hypertensive women

18 Nov 2023

Torsemide as good as furosemide for treating de novo, chronic heart failure

18 Nov 2023

Among patients with heart failure (HF), those who have de novo HF have better outcomes than those who have worsening chronic HF status, but treatment with torsemide yields 12-month outcomes that are similar to that observed with furosemide regardless of HF type, according to a post hoc analysis of the TRANSFORM-HF trial.

Torsemide as good as furosemide for treating de novo, chronic heart failure

18 Nov 2023

TAVR outperforms surgery through 4 years in low-risk patients with severe AS

17 Nov 2023 by

Among low surgical-risk patients with severe aortic stenosis (AS), those who underwent transcatheter aortic valve replacement (TAVR) have better valve performance and clinical and haemodynamic outcomes up to 4 years compared with those who underwent surgical aortic valve replacement (SAVR), according to the EVOLUT Low Risk trial presented at TCT 2023.

TAVR outperforms surgery through 4 years in low-risk patients with severe AS

17 Nov 2023

Low-sodium diet delivers rapid BP-lowering effect

16 Nov 2023 by

In the CARDIA-SSBP study, low sodium intake led to a rapid reduction in blood pressure (BP) in middle-aged individuals.

Low-sodium diet delivers rapid BP-lowering effect

16 Nov 2023

Original New Drug Application Approvals by US FDA (01-15 November 2023)

15 Nov 2023

New drug applications approved by US FDA as of 01-15 November 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 November 2023)

15 Nov 2023

Paclitaxel-coated devices do not increase mortality risk

14 Nov 2023 by

An updated patient-level meta-analysis refutes claims that paclitaxel-coated devices for femoropopliteal interventional procedures heighten the risk of death. The recent study presented at TCT 2023 has found no association between exposure to paclitaxel and mortality.

Paclitaxel-coated devices do not increase mortality risk

14 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

Dapagliflozin offers cardioprotection in HF patients with T2D

Dapagliflozin offers cardioprotection in HF patients with T2D

Secondary hypertension prevalent in hypertensive children, especially girls

Secondary hypertension prevalent in hypertensive children, especially girls

Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity

Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity

6-month resistance training eases platelet activation in hypertensive women

6-month resistance training eases platelet activation in hypertensive women

Torsemide as good as furosemide for treating de novo, chronic heart failure

Torsemide as good as furosemide for treating de novo, chronic heart failure

TAVR outperforms surgery through 4 years in low-risk patients with severe AS

TAVR outperforms surgery through 4 years in low-risk patients with severe AS

Low-sodium diet delivers rapid BP-lowering effect

Low-sodium diet delivers rapid BP-lowering effect

Original New Drug Application Approvals by US FDA (01-15 November 2023)

Original New Drug Application Approvals by US FDA (01-15 November 2023)

Paclitaxel-coated devices do not increase mortality risk

Paclitaxel-coated devices do not increase mortality risk